Amylyx Pharmaceuticals Inc. (AMLX)
AMLX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$26.85
-2.29% on the day
Market cap
$3.4B
Mid cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
-$144.7M
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | AMLX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001658551 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$144.7M |
| Operating income | -$153.3M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | -100.0% |
| Cash | $226.7M |
| Total assets | $332.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-20 |
| Latest annual report | 10-K | 2026-03-03 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-09-08 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 438 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.9% |
| 1 month | -18.8% |
| 3 months | +58.2% |
| Year to date | +122.8% |
| 1 year | +90.7% |
| From 52-week high | -32.1% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VKTX | Viking Therapeutics Inc. | $26.65 | -5.96% | $3.3B |
| XENE | Xenon Pharmaceuticals Inc. Common Shares | $34.42 | -3.88% | $3.3B |
| IDYA | IDEAYA Biosciences Inc. | $34.26 | -4.99% | $3.3B |
| ARQT | Arcutis Biotherapeutics Inc. | $26.09 | -0.50% | $3.3B |
| PBLS | Parabilis Medicines Inc. | $26.85 | -7.25% | $3.3B |
| LEGN | Legend Biotech Corporation | $17.88 | +0.45% | $3.5B |
| ACAD | ACADIA Pharmaceuticals Inc. | $18.62 | -4.07% | $3.2B |
| OGN | Organon & Co. Common Stock | $13.77 | 0.00% | $3.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier